See more : Yuyu Pharma, Inc. (000225.KS) Income Statement Analysis – Financial Results
Complete financial analysis of ZimVie Inc. (ZIMV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZimVie Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Hawaiian Vintage Chocolate Co. (HWVI) Income Statement Analysis – Financial Results
- Andretti Acquisition Corp. (WNNR-UN) Income Statement Analysis – Financial Results
- Zhejiang Yangfan New Materials Co., Ltd. (300637.SZ) Income Statement Analysis – Financial Results
- Termbray Industries International (Holdings) Limited (0093.HK) Income Statement Analysis – Financial Results
- NORD.investments Fondsmæglerselskab A/S (NORD.CO) Income Statement Analysis – Financial Results
ZimVie Inc. (ZIMV)
About ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 457.43M | 913.86M | 1.01B | 912.40M | 1.06B | 1.10B |
| Cost of Revenue | 167.05M | 300.79M | 385.80M | 312.90M | 333.90M | 382.70M |
| Gross Profit | 290.38M | 613.08M | 628.80M | 599.50M | 721.60M | 716.40M |
| Gross Profit Ratio | 63.48% | 67.09% | 61.98% | 65.71% | 68.37% | 65.18% |
| Research & Development | 26.16M | 62.69M | 61.30M | 49.20M | 55.60M | 52.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 248.96M | 523.97M | 554.40M | 533.50M | 605.40M | 599.90M |
| Other Expenses | 46.20M | 80.87M | 86.20M | 85.50M | 83.40M | -600.00K |
| Operating Expenses | 321.32M | 667.53M | 701.90M | 668.20M | 744.40M | 747.40M |
| Cost & Expenses | 488.37M | 968.31M | 1.09B | 981.10M | 1.08B | 1.13B |
| Interest Income | 0.00 | 18.28M | 292.00K | 302.00K | 100.00K | 0.00 |
| Interest Expense | 20.23M | 18.28M | 300.00K | 300.00K | 100.00K | 100.00K |
| Depreciation & Amortization | 121.69M | 122.79M | 129.70M | 134.30M | 135.10M | 147.70M |
| EBITDA | 91.07M | 79.16M | 28.70M | -86.70M | 107.50M | -326.40M |
| EBITDA Ratio | 19.91% | 7.87% | 5.53% | 7.37% | 10.66% | 10.56% |
| Operating Income | -30.94M | -50.85M | -73.60M | -67.10M | -22.60M | -473.50M |
| Operating Income Ratio | -6.76% | -5.56% | -7.25% | -7.35% | -2.14% | -43.08% |
| Total Other Income/Expenses | -19.91M | -8.01M | -123.12M | 1.31M | 100.00K | -700.00K |
| Income Before Tax | -50.85M | -109.92M | -101.30M | -221.30M | -27.70M | -474.20M |
| Income Before Tax Ratio | -11.12% | -12.03% | -9.98% | -24.25% | -2.62% | -43.14% |
| Income Tax Expense | 5.20M | -46.04M | -6.00M | -42.30M | 200.00K | -14.80M |
| Net Income | -393.28M | -63.88M | -95.30M | -179.00M | -27.90M | -460.40M |
| Net Income Ratio | -85.98% | -6.99% | -9.39% | -19.62% | -2.64% | -41.89% |
| EPS | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| EPS Diluted | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| Weighted Avg Shares Out | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
| Weighted Avg Shares Out (Dil) | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
ZimVie: Downgrade To A Hold On Valuation And Fundamentals
ZimVie to Present at the Stifel 2023 Jaws & Paws Conference
ZimVie to Report First Quarter 2023 Financial Results on May 3, 2023
Why ZimVie Stock Was Plummeting on Thursday
ZimVie to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023
ZimVie to Present at the 41st Annual J.P. Morgan Healthcare Conference
ZimVie Inc. (ZIMV) Q3 2022 Earnings Call Transcript
ZimVie to Report Third Quarter 2022 Financial Results on November 9, 2022
ZimVie to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
ZimVie: Disappointing Guidance Prompts Caution
Source: https://incomestatements.info
Category: Stock Reports